These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 4962524)

  • 81. [Tuberculostatic active N,N'-diarylthioureas. 1].
    Winkelmann E; Wagner WH; Hilmer H
    Arzneimittelforschung; 1969 Apr; 19(4):543-58. PubMed ID: 4977575
    [No Abstract]   [Full Text] [Related]  

  • 82. [Study of tuberculostatic activity and blood concentration of new agents--rifampicin and ethambutol--in patients with pulmonary tuberculosis].
    Mkrtchian SV; Ushkin VV
    Antibiotiki; 1971 May; 16(5):472-7. PubMed ID: 5002224
    [No Abstract]   [Full Text] [Related]  

  • 83. [Terminal causes of death in patients suffering from pulmonary tuberculosis in relation to the drug sensitivity of the strains of Mycobacterium tuberculosis].
    Daddi G; Lucchesi M; Mancini P; Rossi P; Sbampato M; Storniello G
    Ann Ist Carlo Forlanini; 1969; 29(4):339-48. PubMed ID: 5004332
    [No Abstract]   [Full Text] [Related]  

  • 84. [Approaches to combined therapy of pulmonary tuberculosis in adolescents excreting drug-resistant Mycobacterium tuberculosis].
    Firsova VA; Rusakova LI; Grigor'eva ZP; Ryzhova AP; Iatskova TV; Poluéktova FG
    Probl Tuberk; 2001; (1):28-30. PubMed ID: 11337776
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Drug resistant Mycobacterium tuberculosis.
    Lim VK
    Med J Malaysia; 1993 Jun; 48(2):97-8. PubMed ID: 8350810
    [No Abstract]   [Full Text] [Related]  

  • 86. Cochrane systematic review of directly observed therapy for treating tuberculosis: good analysis of the wrong outcome.
    Rusen ID; Aït-Khaled N; Alarcón E; Billo N; Bissell K; Boillot F; Caminero J; Chiang CY; Clevenbergh P; Dhliwayo P; Dlodlo R; Enarson DA; Ferroussier O; Fujiwara PI; Heldal E; Hinderaker SG; Kim SJ; Lienhardt C; Rieder HL; Trébucq A; Van Deun A; Wilson N
    Int J Tuberc Lung Dis; 2007 Feb; 11(2):120-1. PubMed ID: 17263279
    [No Abstract]   [Full Text] [Related]  

  • 87. [Resistance of tuberculosis mycobacteria isolated from resected lungs].
    Usov II; Belousov AV
    Probl Tuberk; 1967; 45(12):68. PubMed ID: 4974358
    [No Abstract]   [Full Text] [Related]  

  • 88. Particulate respirators and tuberculosis transmission.
    NEHW Health Watch; 1992; 12(2):8-9. PubMed ID: 1478548
    [No Abstract]   [Full Text] [Related]  

  • 89. [Some problems of the evaluation of new, tuberculostatic-acting substances in the test tube].
    Trnka L; Urbancík R; Havel A
    Wien Med Wochenschr; 1967 Feb; 117(6):146-51. PubMed ID: 4969980
    [No Abstract]   [Full Text] [Related]  

  • 90. [Possibility of the intensification of tuberculosis chemotherapy and its limits].
    Naito M; Kanai K; Kondo E; Yamashita H; Matsui K
    Kekkaku; 1969 Nov; 44(11):377-93. PubMed ID: 4982567
    [No Abstract]   [Full Text] [Related]  

  • 91. Comparative studies of various antituberculosis drug regimens by means of serum antimycobacterial activity tests in man.
    Hokama S
    Jpn J Tuberc; 1967 Jul; 14(1):55-65. PubMed ID: 5300098
    [No Abstract]   [Full Text] [Related]  

  • 92. Some remarks on the recent bacteriological research on tuberculosis.
    Daddi G; Lucchesi M; Zubiani M
    Indian J Chest Dis Allied Sci; 1982; 24(2-3):164-9. PubMed ID: 7166352
    [No Abstract]   [Full Text] [Related]  

  • 93. [Clinical experiences with a new antitubercular drug: 4,4'-diisoamyloxythiocarbanilide (isoxyl)].
    Durigato S
    G Ital Chemioter; 1965; 12(1):110-20. PubMed ID: 5894081
    [No Abstract]   [Full Text] [Related]  

  • 94. Isoxyl.
    Tubercle; 1965 Sep; 46(3):298-300. PubMed ID: 5893355
    [No Abstract]   [Full Text] [Related]  

  • 95. Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences.
    de Kantor IN; Barrera L
    Medicina (B Aires); 2007; 67(3):231-7. PubMed ID: 17628909
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Criteria of the resistance of Mycobacterium tuberculosis against bacteriostatic level of pharmacological preparations in patient's blood].
    Kozulitsina TI; Afanas'eva IP
    Probl Tuberk; 1972; 50(4):76-9. PubMed ID: 4623070
    [No Abstract]   [Full Text] [Related]  

  • 97. Some correlations between chemical structure and mode of action of tuberculostatica. Researches on capreomycin and isoxyl.
    Păunescu E; Stoinescu M; Zaharescu C; Drăguşanu E
    Antibiot Chemother; 1970; 16():10-6. PubMed ID: 4108883
    [No Abstract]   [Full Text] [Related]  

  • 98. [Activity of Isoxyl on Mycobacterium kansasii; studies in vitro and in the pneumoconiotic guinea pig].
    Tacquet A; Devulder B; Tison F; Martin JC
    Antibiot Chemother; 1970; 16():160-76. PubMed ID: 5535612
    [No Abstract]   [Full Text] [Related]  

  • 99. Isoxyl particles for pulmonary delivery: In vitro cytotoxicity and potency.
    Wang C; Hickey AJ
    Int J Pharm; 2010 Aug; 396(1-2):99-104. PubMed ID: 20600722
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Point mutations within the fatty acid synthase type II dehydratase components HadA or HadC contribute to isoxyl resistance in Mycobacterium tuberculosis.
    Gannoun-Zaki L; Alibaud L; Kremer L
    Antimicrob Agents Chemother; 2013 Jan; 57(1):629-32. PubMed ID: 23114755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.